| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7da5c8e8c3e8261efe7e698c7198681b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c6bb13dbc4237622890dd2821bef4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f211ca739ec5e994fbe7d6c28bf241a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d12b35c0dd9adfb167b3b4f383afe93 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43563 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 |
| filingDate |
2002-07-16^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03c79344e3490a96a71bbacba4ea00ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3f0f64421ca2eb3ccb09fb94e3927a2 |
| publicationDate |
2003-01-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03008442-A1 |
| titleOfInvention |
Novel acyl peptides with leishmanicidal activity |
| abstract |
The invention relates to synthesised novel hybrid cecropin-melittin peptides having a bactericidal and leishmanicidal activity. Said peptides are derivatives of the lead peptide CA(1-7)M(2-9) and are acylated in one of the amino groups thereof with fatty acids having a variable chain length. In the face of Leishmania, the acylation of the peptides with fatty acids increases the activity of the peptide in relation to both the promastigote and amastigote form thereof. The lethal mechanism is directly related to the permeabilisation of the plasmatic membrane. The inventive peptides provide an extremely useful alternative given the scarcity of novel drugs against Leishmania and the appearance of resistance to antibiotics. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017198853-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8697637-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IT-UA20163612-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011095939-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8026219-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2955772-A1 |
| priorityDate |
2001-07-20^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |